3 Domestic Brands, Anti-Malarial Leader and Anti-Retroviral Ingredients Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Ipca Laboratories and Laurus Labs

Branded and API pharma stocks let investors follow companies that earn from prescription brands as well as from ingredients sold to other drug makers. JB Chemicals and Pharmaceuticals, Ipca Laboratories and Laurus Labs combine domestic brands, anti-malarial strength and anti-retroviral ingredients.

This list covers three branded and API pharma stocks with complete current figures: JB Chemicals and Pharmaceuticals, Ipca Laboratories and Laurus Labs. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Branded and API Pharma Stocks?

Branded and API pharma stocks are listed companies that sell prescription brands in India and supply active ingredients and formulations to global customers. Their earnings depend on prescription growth, capacity use and the mix of products.

Branded and API Pharma Stocks at a Glance

On valuation, Ipca Laboratories trades at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals and Laurus Labs trade above it, which reflects the growth the market already expects. Readers comparing branded and API pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Branded and API Pharma Stocks Have a Strong Roadmap in India?

Branded and API pharma stocks have a strong roadmap in India because rising chronic and infectious disease care, wider access to medicines and global sourcing of ingredients support steady growth.

• Prescription growth. Strong brands keep winning share with doctors.
• Ingredient supply. Global drug makers source more active ingredients from Indian plants.
• Therapy expansion. Moving into oncology and other areas widens the base.

Why JB Chemicals and Pharmaceuticals Features Among These Branded and API Pharma Stocks

Among the branded and API pharma stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.

The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 36.0.

Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.

Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.

Why Ipca Laboratories Features Among These Branded and API Pharma Stocks

Among the domestic brand pharma shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%.

In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Why Laurus Labs Features Among These Branded and API Pharma Stocks

Among the three companies on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.

In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%.

Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.

Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.

JB Chemicals and Pharmaceuticals vs Ipca Laboratories vs Laurus Labs on Key Financials

The table below sets the three branded and API pharma stocks side by side on revenue, profit and margin, using reported figures.

JB Chemicals and Pharmaceuticals posts the highest return on equity in this group at 17.1%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and JB Chemicals and Pharmaceuticals shows the fastest revenue growth with a 14.3% compound annual rate. A useful habit with branded and API pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Branded and API Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these branded and API pharma stocks, the main points are: Long-term domestic brand pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Pricing rules. Price controls can limit the pace of growth for some medicines.
• Plant approvals. Regulatory delays can push out product launches.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter branded and API pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Branded and API Pharma Stocks

Branded and API pharma stocks reward investors who follow prescription trends, plant utilisation and new launches together. JB Chemicals and Pharmaceuticals, Ipca Laboratories and Laurus Labs each have levers beyond a single product. Based on the 21 October 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Ipca Laboratories at Rs 1,918.9 and Laurus Labs at Rs 2,012.5. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these branded and API pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track branded and API pharma stocks, set price alerts and get research-backed stock ideas.

What are branded and API pharma stocks?

Ans. Branded and API pharma stocks are listed companies that sell prescription brands in India and supply active ingredients and formulations to global customers. Their earnings depend on prescription growth, capacity use and the mix of products. This list looks at three of them, JB Chemicals and Pharmaceuticals, Ipca Laboratories and Laurus Labs, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which branded and API pharma stocks are covered in this list?

Ans. This list covers JB Chemicals and Pharmaceuticals, Ipca Laboratories and Laurus Labs. Based on the 21 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Ipca Laboratories at Rs 1,918.9 and Laurus Labs at Rs 2,012.5. Their return on equity ranges from 14.2% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 14.3%.

Why do branded and API pharma stocks have a strong future roadmap in India?

Ans. Branded and API pharma stocks have a strong roadmap in India because rising chronic and infectious disease care, wider access to medicines and global sourcing of ingredients support steady growth. The main drivers are as follows. Prescription growth. Strong brands keep winning share with doctors. Ingredient supply. Global drug makers source more active ingredients from Indian plants. Therapy expansion. Moving into oncology and other areas widens the base. Together these factors give the companies on this list a visible path for growth over the coming years.

How has JB Chemicals and Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 36.0. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

How has Laurus Labs performed financially?

Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What risks should investors check before buying branded and API pharma stocks?

Ans. Investors should check a few risks before buying branded and API pharma stocks. Pricing rules. Price controls can limit the pace of growth for some medicines. Plant approvals. Regulatory delays can push out product launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of branded and API pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.